Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05815290

Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer

A Phase II Trial of Cadonilimab in Locally Advanced Stage II/III MSI-H/dMMR Colorectal Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Interventions Cadonilimab

Updated 3 times since 2023 Last updated: Apr 13, 2023 Started: Mar 29, 2023 Primary completion: Sep 30, 2024 Completion: Mar 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates dMMR Colorectal Cancer and is currently actively recruiting participants. Cancer Institute and Hospital, Chinese Academy of Medical Sciences leads this study, which shows 3 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Mar 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China